When a pen is a drug and a device at once

One object, two categories

A prefilled pen holds a drug. It is also a mechanical device that meters and delivers a dose. Federal law has separate rulebooks for those two things, written decades apart, with different vocabularies.

Part 4 of title 21 exists to settle which rulebook applies when both are in the same object. Its heading is Regulation of Combination Products, and its first subpart covers manufacturing.

Section 4.1 states what that subpart does. It "establishes which current good manufacturing practice requirements apply to these products." It also provides "a regulatory framework for designing and implementing the current good manufacturing practice operating system at facilities that manufacture co-packaged or single-entity combination products."

The two shapes named there matter. A single-entity product is one physical thing. A co-packaged product is two things sold in one box.

The vocabulary that does the work

Section 4.2 sets the terms, and three of them carry most of the weight.

A constituent part is defined as "a drug, device, or biological product that is part of a combination product." That is the unit the rest of the part reasons about.

The second is the one that surprises people. "A device that is a constituent part of a combination product is considered a finished device" within the meaning of the device quality regulation.

The third mirrors it. A drug other than a medical gas that is a constituent part "is considered a drug product within the meaning of the drug current good manufacturing practice (CGMP) requirements."

So being part of something larger does not downgrade either half. Each constituent part is treated as the finished article of its own kind.

The part also defines what a manufacturer is doing, expansively. Manufacture "includes, but is not limited to, designing, fabricating, assembling, filling, processing, testing, labeling, packaging, repackaging, holding, and storage."

Which rules apply, in one section

Section 4.3 is a short list, and it is the clearest statement of the whole scheme.

The drug rules in parts 210 and 211 "apply to a combination product that includes a drug constituent part other than a medical gas."

The device quality management system regulation in part 820 is on the same list, applying "to a combination product that includes a device constituent part."

Biological product requirements apply where there is a biological constituent part to which they would apply on its own. Current good tissue practice requirements including donor eligibility apply where there is a human cell or tissue product.

The structure is additive rather than selective. A pen containing a drug is subject to both the drug rules and the device rules, because it contains a constituent part of each kind.

The choice a manufacturer gets

Section 4.4 is where the practical relief lives, and it is the reason this scheme is workable at all.

Compliance "shall be achieved through the design and implementation of a current good manufacturing practice operating system," and there are two ways to demonstrate it.

The first is straightforward and heavy. Show compliance with "The specifics of each set of current good manufacturing practice regulations listed under § 4.3 as they apply to each constituent part."

The second is the streamlined route. A manufacturer can operate one system, show it meets one of the two regimes in full, and then show that specific named provisions of the other are also satisfied. The regulation states the payoff directly: "upon demonstration that these requirements have been satisfied, no additional showing of compliance with respect to the QMSR" is needed.

The point is that one quality system can carry both obligations. The exercise is proving the gaps are closed, not building two organizations.

Why the same clause numbers keep appearing

The device side of this scheme runs through part 820, the Quality Management System Regulation, which incorporates an international standard by reference and points at numbered clauses of it.

That is why a reader running into part 4 or part 820 sees references to clauses rather than to spelled-out requirements. The requirements themselves live in a standard published by a standards body, not in the Code.

That standard is copyrighted, and its text is not reproduced here or anywhere on this site, on the same principle applied to pharmacopeial chapters.

What is checkable from the Code alone is the structure: which regime applies to which constituent part, and which route a manufacturer may take to show it complies.

What this does and does not say about a peptide product

Whether any given product is a combination product is not settled by part 4. It is settled under part 3, which is covered separately here.

A vial and a separately purchased syringe are two purchases, not obviously one product. A pen with the drug inside it is a single object containing both kinds of constituent part. Between those poles sit kits, co-packaged needle sets and delivery systems of various shapes, and the classification of any particular one is a determination, not an inference.

Nothing here asserts that any marketed peptide product is or is not a combination product, and no seller is named or assessed.

What the part gives a reader is a correct expectation. If a product genuinely is one, then both manufacturing regimes are in play, and the device half is treated as a finished device in its own right rather than as an accessory.

What was not verified here

Three things, stated plainly so nobody reads more into this than it carries.

The text of the incorporated international standard was not read, so nothing here characterizes what any clause of it requires.

No product on this site was classified. No inspection outcome, no application status and no manufacturer's chosen compliance route was examined, because none of that is in the Code.

And this is a summary of a regulation, not legal advice. Part 4 is the map; whether a given object is on it is a determination made elsewhere.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. Title 21 Code of Federal Regulations section 4.1, What is the scope of this subpart? — Electronic Code of Federal Regulations, Office of the Federal Register, January 2013
2. Title 21 Code of Federal Regulations section 4.2, How does FDA define key terms and phrases in this subpart? — Electronic Code of Federal Regulations, Office of the Federal Register, June 2024
3. Title 21 Code of Federal Regulations section 4.3, What current good manufacturing practice requirements apply to my combination product? — Electronic Code of Federal Regulations, Office of the Federal Register, June 2024
4. Title 21 Code of Federal Regulations section 4.4, How can I comply with these current good manufacturing practice requirements for a co-packaged or single-entity combination product? — Electronic Code of Federal Regulations, Office of the Federal Register, June 2024